The global human insulin market was valued at $23,981.6 million in 2014. The market is expected to grow at a CAGR of 12.5% during the period 2015 to 2020, to reach $48,487.7 million value by 2020. The global human insulin market is being driven by increasing prevalence of diabetic population, and rise in aging population. Diabetes is a chronic and non-communicable disease, and its global prevalence is increasing enormously. Rising prevalence of obesity, rising awareness about diabetic care, and technological advancement in insulin delivery devices are some of the factors driving the growth of the global human insulin market. Growing demand of biosimilar drugs, due to its cost effectiveness, pose an opportunity for the growth of the human insulin market. In addition, increasing usage of insulin pens for the administration of insulin helps to inject the accurate dose of insulin at a time. However, high insulin analog cost and strict regulatory requirements for approval of human insulin are inhibiting the growth of the global human insulin market.
On the basis of type of human insulin, the modern human insulin commands the larger share in the global market. The modern human insulin is also expected to grow at a CAGR (of 13%) than traditional human insulin during 2015 to 2020. The modern human insulin can be further categorized as long acting human insulin, rapid acting human insulin and premixed human insulin; wherein, the long acting human insulin commands the largest share in modern human insulin market but the premixed human insulin exhibited the highest growth rate. The long acting human insulin is prescribed by physicians for the treatment of type 2 diabetes. It is absorbed slowly and works for long time to control the sugar level between meal and sleep. It is administered once or twice a day and the onset time for long acting human insulin is 1 hour, and has its effect for 20 hours to 26 hours.
Increasing prevalence of diabetes, increasing number of geriatric population, rising prevalence of obesity and increasing R&D investment for more effective insulin are driving the growth of the human insulin market in North America. The North American human insulin market is expected to grow by a CAGR of 11.8% during the period 2015 to 2020. In Europe, according to International Diabetic Federation in 2013, approximately 52 million people were suffering from diabetes in Europe. The European human insulin market is expected to grow by a CAGR of 12.6% during the period 2015 to 2020. Thus, increasing prevalence of diabetes would increase the usage of human insulin.
Also, in Asia-Pacific, several government initiatives are implemented to create awareness about prevention and treatment of diabetes. The government is also taking initiatives to improve healthcare infrastructure and provide treatment in rural areas. In Asia-Pacific, the human insulin market is expected to witness CAGR of 13.9% during the period 2015 to 2020, to achieve $12,074.3 million value by 2020.
The global human insulin market has a fragmented structure with large number of companies operating in the market. The key players in the human insulin market include Sanofi, Novo Nordisk A/S, Eli Lilly and Company, GlaxoSmithKline Plc, Pfizer, Inc., Merck & Co., and Julphar.
.News Courtesy: P&S Market Research